Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review
Abstract Purpose With the continuous development and progress of next-generation gene sequencing technology, many types of anaplastic lymphoma kinase (ALK) rearrangement have been discovered. However, in small cell lung cancer (SCLC), ALK rearrangement is extremely rare and there is no standard trea...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-02-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06091-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863272874442752 |
|---|---|
| author | Mingyue Wang Hongzhi Liu Ruixin Zhang Runyu Li Xiaoyu Qin Fangling Ning Lijun Tian |
| author_facet | Mingyue Wang Hongzhi Liu Ruixin Zhang Runyu Li Xiaoyu Qin Fangling Ning Lijun Tian |
| author_sort | Mingyue Wang |
| collection | DOAJ |
| description | Abstract Purpose With the continuous development and progress of next-generation gene sequencing technology, many types of anaplastic lymphoma kinase (ALK) rearrangement have been discovered. However, in small cell lung cancer (SCLC), ALK rearrangement is extremely rare and there is no standard treatment protocol. By reviewing the literature, we summarized the previously reported cases of ALK-positive SCLC, and discussed the significance of molecular detection. Method We report a rare patient with EML4-ALK fusion gene SCLC, a 41-year-old woman with no history of smoking or drinking, who was admitted to the hospital with chest tightness, dyspnea, and cough and sputum. Extensive SCLC (cT4N0M1) was diagnosed after relevant examination and pathological examination. The patient relapsed again six months after receiving first-line chemoradiotherapy. And the patient still developed disease progression (PD) after continued multi-line treatment including chemotherapy, immunotherapy, and anti-vascular therapy. ALK inhibitor is currently being taken orally, and significant clinical response has been achieved. Progression-free survival (PFS) was more than 8 months. Result ALK rearrangement of SCLC is rare. The stage IV patient with ALK rearrangement benefit from ALK inhibitors after multiline therapy. Conclusion For patients with ALK-positive SCLC, ALK inhibitors may be a reliable treatment option. |
| format | Article |
| id | doaj-art-5dceb80ff4674c7087f808967dd5a5a8 |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-5dceb80ff4674c7087f808967dd5a5a82025-02-09T12:10:42ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-02-0115121810.1007/s00432-025-06091-3Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature reviewMingyue Wang0Hongzhi Liu1Ruixin Zhang2Runyu Li3Xiaoyu Qin4Fangling Ning5Lijun Tian6Department of Oncology, Binzhou Medical University HospitalDepartment of Traumatic Orthopedics, Binzhou Medical University HospitalDepartment of Oncology, Binzhou Medical University HospitalDepartment of Oncology, Binzhou Medical University HospitalDepartment of Oncology, Binzhou Medical University HospitalDepartment of Oncology, Binzhou Medical University HospitalDepartment of Oncology, Binzhou Medical University HospitalAbstract Purpose With the continuous development and progress of next-generation gene sequencing technology, many types of anaplastic lymphoma kinase (ALK) rearrangement have been discovered. However, in small cell lung cancer (SCLC), ALK rearrangement is extremely rare and there is no standard treatment protocol. By reviewing the literature, we summarized the previously reported cases of ALK-positive SCLC, and discussed the significance of molecular detection. Method We report a rare patient with EML4-ALK fusion gene SCLC, a 41-year-old woman with no history of smoking or drinking, who was admitted to the hospital with chest tightness, dyspnea, and cough and sputum. Extensive SCLC (cT4N0M1) was diagnosed after relevant examination and pathological examination. The patient relapsed again six months after receiving first-line chemoradiotherapy. And the patient still developed disease progression (PD) after continued multi-line treatment including chemotherapy, immunotherapy, and anti-vascular therapy. ALK inhibitor is currently being taken orally, and significant clinical response has been achieved. Progression-free survival (PFS) was more than 8 months. Result ALK rearrangement of SCLC is rare. The stage IV patient with ALK rearrangement benefit from ALK inhibitors after multiline therapy. Conclusion For patients with ALK-positive SCLC, ALK inhibitors may be a reliable treatment option.https://doi.org/10.1007/s00432-025-06091-3ALK positiveSmall cell lung cancerTargeted therapyImmunotherapyChemotherapy |
| spellingShingle | Mingyue Wang Hongzhi Liu Ruixin Zhang Runyu Li Xiaoyu Qin Fangling Ning Lijun Tian Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review Journal of Cancer Research and Clinical Oncology ALK positive Small cell lung cancer Targeted therapy Immunotherapy Chemotherapy |
| title | Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review |
| title_full | Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review |
| title_fullStr | Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review |
| title_full_unstemmed | Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review |
| title_short | Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review |
| title_sort | small cell lung cancer with eml4 alk fusion report of a case responding to alk tki and literature review |
| topic | ALK positive Small cell lung cancer Targeted therapy Immunotherapy Chemotherapy |
| url | https://doi.org/10.1007/s00432-025-06091-3 |
| work_keys_str_mv | AT mingyuewang smallcelllungcancerwitheml4alkfusionreportofacaserespondingtoalktkiandliteraturereview AT hongzhiliu smallcelllungcancerwitheml4alkfusionreportofacaserespondingtoalktkiandliteraturereview AT ruixinzhang smallcelllungcancerwitheml4alkfusionreportofacaserespondingtoalktkiandliteraturereview AT runyuli smallcelllungcancerwitheml4alkfusionreportofacaserespondingtoalktkiandliteraturereview AT xiaoyuqin smallcelllungcancerwitheml4alkfusionreportofacaserespondingtoalktkiandliteraturereview AT fanglingning smallcelllungcancerwitheml4alkfusionreportofacaserespondingtoalktkiandliteraturereview AT lijuntian smallcelllungcancerwitheml4alkfusionreportofacaserespondingtoalktkiandliteraturereview |